Journal Finder

Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.

Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:

Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including:

HIV Clinical Trials is devoted exclusively to keeping you in touch with the latest developments and techniques in HIV/AIDS therapeutics. This is where you'll gain a more complete picture of worldwide developments.HIV Clinical Trials coverage includes:- the results of therapeutic, diagnostic, or preventive clinical trials, reports of clinical research, and meta-analyses- pilot studies- methodological papers- review articles- quality of life and pharmacoeconomic evaluations- controversies- invited editorial comments- book reviews- letters to the editor- abstracts of conferences.

HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.

Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal:

The Indian Journal of Pharmacology (ISSN 0253-7613) is an official organ of the Indian Pharmacological Society. The first issue of the journal came out in 1969 and it was published Bimonthly. In 1997 it became a bimonthly publication. IJP publishes original research articles, reviews, research letters and correspondences.

The journal Infectio is the official scientific publication of the Colombian Association of Infectious Diseases (Asociación Colombiana de Infectología) (ACIN). It publishes four issues per year with articles related to the specialty, in areas of clinical, pharmacological or microbiological research. All the manuscripts are assessed by the Journal Editorial Committee after receiving the evaluations of two external reviewers who assess the articles in the form of a blind peer review.

Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS).Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, and arthritic conditions. The journal has five main interest areas: Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress statesRheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugsGastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agentsNeuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and painNovel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs.Requirements for manuscripts on the pharmacological or inflammatory properties of, natural products are described in the editorial Inflammopharmacology Vol. 15, issue 5 or on the journal website: www.springer.com/10787.

International Clinical Psychopharmacology continues to maintain its high standing in publication of research and clinical practice within the field of psychopharmacology. This respected journal is largely concerned with psychotropic drugs, covering phase I-IV studies, clinical studies, side-effects and epidemiology. Papers deal with studies on both healthy volunteers and patients. Regular volume indexes make the journal an invaluable reference in the field. For more information, visit www.intclinpsychopharm.com.

The International Journal for Parasitology – Drugs and Drug Resistance publishes the results of original research in the area of anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal also covers research into natural products as anti-parasitic agents, and bioactive parasite products. Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.A list showing the types of articles that are considered is included below. Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. Because of its breadth of organism coverage, all contributions should include relevant information about the parasite of interest in order to be comprehensible to non-experts in the particular subject of the articles. The principal form of publication is the full length article which contains substantial results from a major program of research. The journal also accepts brief reports that have similar subject scope as the full-length article, but do not merit a full-length publication.In addition, the journal provides a medium for highlighting selected articles reporting highly significant original findings, as Editor's Choice Manuscripts. It also commissions articles with emphasis on shorter, focused Reviews of topical issues and strategically important subjects. The journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions".This title is fully open access and therefore funded not through library subscription payments but through author fees. If you would like your article to be published open access, but you genuinely cannot afford these fees, then individual waiver requests are considered on a case-by-case basis and may be granted in cases of genuine need. Priority for this waiver programme will be given to applications by authors from countries eligible for the Research4Life programme (see http://www.research4life.org/institutions.html).Types of articles considered:Compound library screening for inhibitors against enzymes or whole parasitesDrug target validation (chemical and/or genetic)Drug target identification (must include some inhibitor studies rather than characterisation of an enzyme, for example)Drug structure-activity relationship studiesMechanisms of drug action and resistanceReports of the development of drug resistance both in the field and laboratoryStudies on drug toxicity to the host (either on single host cells or whole organism)Reports on toxicity in the fieldComputational approaches to drug discovery or drug-target identificationDevelopment of assays directed at screening for inhibitorsDrug combination studiesNatural products as anti-parasitic agentsBioactive products produced by parasitesUse of live parasites as immunomodulatory agentsEpidemiological aspects of the emergence and spread of parasite drug resistanceHuman clinical trials

The International Journal of Antimicrobial Agents provides comprehensive and up-to-date peer reviewed reference information on the physical, pharmacological, in vitro and clinical properties of individual antimicrobial agents (antiviral agents, antiparasitic agents, antibacterial agents, antifungal agents, etc.). In addition, the journal signals new trends and developments in the field through highly authoritative review articles on antimicrobial agents. Special attention is given to articles providing insight into the problems of antimicrobial resistance both in the hospital and in the community. Both solicited reviews by top experts in the mentioned fields and high-quality original research papers are published.Additional information on the ISC and its activities can be found at the ISC Web site at:http://www.ischemo.orgBenefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com